Physician profile
John Mark Pope
NPI 1497312599
$2,604.91
in general payments reported to CMS, 2019-2025
17 companies · $901 in 2025
The $901 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $193 · 2023: $407 · 2024: $861 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.94 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.49 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $264.16 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $232.48 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $228.52 | 2021-2025 | Breztri, Farxiga |
| Pfizer INC. | $166.87 | 2021-2025 | |
| Viatris Specialty LLC | $149.01 | 2025 | Yupelri |
| Lilly USA, LLC | $148.64 | 2021-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $145.64 | 2021-2024 | Yupelri |
| Exact Sciences Corporation | $142.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $66.33 | 2021 | |
| Aimmune Therapeutics, INC. | $65.10 | 2025 | Zenpep |
| Glaxosmithkline, LLC. | $45.69 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Lundbeck LLC | $40.61 | 2024-2025 | Rexulti |
| Nevro Corp. | $31.06 | 2024 | Senza |
| Astellas Pharma US INC | $19.91 | 2024 | Veozah |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.62 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $16.59 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.